title: Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
authors.forename: Fadi J
authors.initials: FJ
authors.lastname: Sawaya
authors.forename: Khaled M
authors.initials: KM
authors.lastname: Musallam
authors.forename: Samir
authors.initials: S
authors.lastname: Arnaout
authors.forename: Ali
authors.initials: A
authors.lastname: Rabah
authors.forename: Jaber
authors.initials: J
authors.lastname: Sawaya
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000150:complications*; D001562:Benzimidazoles / Q000009:adverse effects*; D003328:Coronary Thrombosis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D000069604:Dabigatran; D006801:Humans; D008297:Male; D012008:Recurrence; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014463:Ultrasonography; D014859:Warfarin / Q000008:administration & dosage*; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran